Saturday, 31 October 2026European Markets

GLANBIA PLC And HEINEKEN HOLDING Have A High Dividend Yield And Return On Equity In The Consumer Defensive Sector.

Loading stream...

(VIANEWS) - GLANBIA PLC (GL9.IR) is among this list of stock assets with the highest dividend rate and return on equity on the Consumer Defensive sector.

Financial Asset Price Forward Dividend Yield Return on Equity
GLANBIA PLC (GL9.IR) €13.98 2.25% 11.06%
HEINEKEN HOLDING (HEIO.AS) €80.70 2.13% 14.6%

Several Euronext companies pay out dividends to its shareholders. The dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.

1. GLANBIA PLC (GL9.IR)

2.25% Forward Dividend Yield and 11.06% Return On Equity

Glanbia plc operates as a nutrition company worldwide. The company manufactures and sells sports nutrition and lifestyle nutrition products in various formats, including powders, ready-to-eat bars and snacking foods, and ready-to-drink beverages through various channels, such as specialty retail, online, and gyms, as well the food, drug, mass, and club channels. It also engages in the manufacture and sale of cheese, dairy, and non-dairy nutritional and functional ingredients; and vitamin and mineral premixes. In addition, the company engages in the financing, research and development, property and land dealing, receivables management, management, property leasing, business service, weight management, and bioactive solutions businesses. It operates a portfolio of brands, including Optimum Nutrition, BSN, Isopure, Nutramino, SlimFast, think!, Amazing Grass, Body & Fit, and LevlUp brands. Glanbia plc was founded in 1964 and is headquartered in Kilkenny, Ireland.

Earnings Per Share

As for profitability, GLANBIA PLC has a trailing twelve months EPS of €0.73.

PE Ratio

GLANBIA PLC has a trailing twelve months price to earnings ratio of 19.15. Meaning, the purchaser of the share is investing €19.15 for every euro of annual earnings.

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 11.06%.

Dividend Yield

As maintained by Morningstar, Inc., the next dividend payment is on Mar 23, 2023, the estimated forward annual dividend rate is 0.32 and the estimated forward annual dividend yield is 2.25%.

Volume

Today's last reported volume for GLANBIA PLC is 35868 which is 90.94% below its average volume of 396243.

Revenue Growth

Year-on-year quarterly revenue growth grew by 30.6%, now sitting on 5.64B for the twelve trailing months.

Moving Average

GLANBIA PLC's value is above its 50-day moving average of €13.67 and way above its 200-day moving average of €12.60.

More news about GLANBIA PLC.

2. HEINEKEN HOLDING (HEIO.AS)

2.13% Forward Dividend Yield and 14.6% Return On Equity

Heineken Holding N.V., through its subsidiaries, engages in brewing and selling beer and cider in the Netherlands and internationally. The company's portfolio consists of approximately 300 international, regional, local, and specialty beers and ciders. The company was founded in 1864 and is based in Amsterdam, the Netherlands. Heineken Holding N.V. is a subsidiary of L'Arche Green N.V.

Earnings Per Share

As for profitability, HEINEKEN HOLDING has a trailing twelve months EPS of €4.66.

PE Ratio

HEINEKEN HOLDING has a trailing twelve months price to earnings ratio of 17.32. Meaning, the purchaser of the share is investing €17.32 for every euro of annual earnings.

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 14.6%.

Revenue Growth

Year-on-year quarterly revenue growth grew by 27.7%, now sitting on 28.72B for the twelve trailing months.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, HEINEKEN HOLDING's stock is considered to be overbought (>=80).

More news about HEINEKEN HOLDING.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Data Wave Builds Toward Ivonescimab PDUFA, While Micro-Cap Biotech Exits the Market
Late October 2026 is a dense catalyst window led by ESMO 2026. Daiichi Sankyo's DXd antibody-drug conjugate (ADC) programs (DESTINY-Lung04, DESTINY-Breast11, REJOICE-Ovarian01/02, TUXEDO-3), Guardant's 25 abstracts and the PACE-LUNG ctDNA trial all report there. These feed into the FDA's 14 November 2026 PDUFA date for ivonescimab. Large and mid-cap developers with late-stage data and commercial launches (ZEGFROVY, ANKTIVA, MIUDELLA, lorundrostat, duvakitug) are drawing capital and attention. Spago Nanomedical's board decision to seek a Nasdaq First North delisting (EGM 19 November, application 25 January 2027) shows the capital squeeze on early-stage, single-asset names (Tumorad is Phase I).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,514 source documents archived
Query this data → isubstrate.com